On the public citation graph
The Rationale and Evidence for SGLT2 Inhibitors as a Treatment for Nondiabetic Glomerular Disease
0 signed · 89 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1007/s00125-016-4158-2openalex-snapshot
The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet
inferredcites →https://doi.org/10.1007/s00125-018-4671-6openalex-snapshot
SGLT inhibitor adjunct therapy in type 1 diabetes
inferredcites →https://doi.org/10.1007/s00125-019-4859-4openalex-snapshot
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
inferredcites →https://doi.org/10.1007/s00210-018-1544-yopenalex-snapshot
Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression
inferredcites →https://doi.org/10.1007/s13300-020-00885-zopenalex-snapshot
Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies
inferredcites →https://doi.org/10.1016/j.diabres.2020.108107openalex-snapshot
Comparison of the effects of insulin and SGLT2 inhibitor on the Renal Renin-Angiotensin system in type 1 diabetes mice
inferredcites →https://doi.org/10.1016/j.kint.2018.05.002openalex-snapshot
A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor–dependent pathway after renal injury in mice
inferredcites →https://doi.org/10.1016/j.kint.2019.09.013openalex-snapshot
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
inferredcites →https://doi.org/10.1016/j.phrs.2020.104781openalex-snapshot
Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
inferredcites →https://doi.org/10.1016/j.vph.2018.06.006openalex-snapshot
Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress
inferredcites →https://doi.org/10.1016/s2213-8587(20)30162-5openalex-snapshot
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
inferredcites →https://doi.org/10.1038/ki.2008.145openalex-snapshot
Tubuloglomerular feedback: mechanistic insights from gene-manipulated mice
inferredcites →https://doi.org/10.1038/ki.2014.246openalex-snapshot
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
inferredcites →https://doi.org/10.1038/nrneph.2011.149openalex-snapshot
Cellular and molecular mechanisms of renal fibrosis
inferredcites →https://doi.org/10.1038/nrneph.2012.19openalex-snapshot
Glomerular hyperfiltration: definitions, mechanisms and clinical implications
inferredcites →https://doi.org/10.1038/s41598-018-23420-4openalex-snapshot
Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
inferredcites →https://doi.org/10.1038/s41598-018-25054-yopenalex-snapshot
High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection
inferredcites →https://doi.org/10.1038/s41598-019-41253-7openalex-snapshot
Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
inferredcites →https://doi.org/10.1038/s41598-019-52323-1openalex-snapshot
Tubular Deficiency of Heterogeneous Nuclear Ribonucleoprotein F Elevates Systolic Blood Pressure and Induces Glycosuria in Mice
inferredcites →https://doi.org/10.1038/srep26428openalex-snapshot
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
inferredcites →https://doi.org/10.1056/nejmoa1515920openalex-snapshot
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1611925openalex-snapshot
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1811744openalex-snapshot
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
inferredcites →https://doi.org/10.1056/nejmoa1911303openalex-snapshot
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
inferredcites →https://doi.org/10.1056/nejmoa2024816openalex-snapshot
Dapagliflozin in Patients with Chronic Kidney Disease
inferredcites →https://doi.org/10.1074/jbc.m117.779520openalex-snapshot
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy
inferredcites →https://doi.org/10.1093/ckj/sfaa198openalex-snapshot
SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
inferredcites →https://doi.org/10.1093/ckj/sfy090openalex-snapshot
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
inferredcites →https://doi.org/10.1093/ndt/gfz264openalex-snapshot
Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
inferredcites →https://doi.org/10.1111/dom.12127openalex-snapshot
Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes
inferredcites →https://doi.org/10.1111/dom.12825openalex-snapshot
Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis of randomized controlled trials
inferredcites →https://doi.org/10.1111/dom.13101openalex-snapshot
Effects of sodium‐glucose co‐transporter 2 ( SGLT2 ) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials
inferredcites →https://doi.org/10.1111/jcmm.14233openalex-snapshot
Angiotensin II‐induced redox‐sensitive SGLT1 and 2 expression promotes high glucose‐induced endothelial cell senescence
inferredcites →https://doi.org/10.1111/jdi.13205openalex-snapshot
Failure to confirm a sodium–glucose cotransporter 2 inhibitor‐induced hematopoietic effect in non‐diabetic rats with renal anemia
inferredcites →https://doi.org/10.1124/jpet.113.203869openalex-snapshot
Effects of a New SGLT2 Inhibitor, Luseogliflozin, on Diabetic Nephropathy in T2DN Rats
inferredcites →https://doi.org/10.1136/jim-2017-000445openalex-snapshot
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Urinary Excretion of Intact and Total Angiotensinogen in Patients with Type 2 Diabetes
inferredcites →https://doi.org/10.1152/ajprenal.00264.2020openalex-snapshot
A role for tubular Na+/H+exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin
inferredcites →https://doi.org/10.1152/ajprenal.00370.2019openalex-snapshot
Renal SGLT mRNA expression in human health and disease: a study in two cohorts
inferredcites →https://doi.org/10.1152/ajprenal.00409.2012openalex-snapshot
Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus
inferredcites →https://doi.org/10.1152/ajprenal.00445.2017openalex-snapshot
Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study
inferredcites →https://doi.org/10.1152/ajprenal.00462.2018openalex-snapshot
SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1
inferredcites →https://doi.org/10.1152/ajprenal.00518.2013openalex-snapshot
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
inferredcites →https://doi.org/10.1152/ajprenal.00520.2013openalex-snapshot
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
inferredcites →https://doi.org/10.1159/000499597openalex-snapshot
Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1161/circulationaha.113.005081openalex-snapshot
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
inferredcites →https://doi.org/10.1161/circulationaha.116.021887openalex-snapshot
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
inferredcites →https://doi.org/10.1161/circulationaha.118.037418openalex-snapshot
Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging
inferredcites →https://doi.org/10.1161/jaha.116.004007openalex-snapshot
Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
inferredcites →https://doi.org/10.1172/jci.insight.129034openalex-snapshot
Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules
inferredcites →https://doi.org/10.1172/jci.insight.98720openalex-snapshot
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy
inferredcites →https://doi.org/10.1177/1479164117733626openalex-snapshot
Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis
inferredcites →https://doi.org/10.1371/journal.pone.0054442openalex-snapshot
Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
inferredcites →https://doi.org/10.1371/journal.pone.0144640openalex-snapshot
Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease
inferredcites →https://doi.org/10.1371/journal.pone.0158810openalex-snapshot
Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
inferredcites →https://doi.org/10.14814/phy2.13228openalex-snapshot
Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease
inferredcites →https://doi.org/10.1681/asn.2013060588openalex-snapshot
Functional Role of Glucose Metabolism, Osmotic Stress, and Sodium-Glucose Cotransporter Isoform-Mediated Transport on Na+/H+ Exchanger Isoform 3 Activity in the Renal Proximal Tubule
inferredcites →https://doi.org/10.2337/db11-1029openalex-snapshot
Na+- d -glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion
inferredcites →https://doi.org/10.2337/dc18-1749openalex-snapshot
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
inferredcites →https://doi.org/10.33594/000000003openalex-snapshot
Effects of the SGLT-2 Inhibitor Canagliflozin on Adenine-Induced Chronic Kidney Disease in Rats
inferredcites →https://doi.org/10.33594/000000178openalex-snapshot
Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells
inferredcites →https://doi.org/10.3389/fendo.2019.00441openalex-snapshot
Dapagliflozin Attenuates Renal Tubulointerstitial Fibrosis Associated With Type 1 Diabetes by Regulating STAT1/TGFβ1 Signaling
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1002/jcph.2196openalex-snapshot
Evaluation of the Pharmacokinetics of Dapagliflozin in Patients With Chronic Kidney Disease With or Without Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.1007/s00467-022-05504-6openalex-snapshot
Expectations in children with glomerular diseases from SGLT2 inhibitors
inferred← citeshttps://doi.org/10.1007/s11255-024-04141-2openalex-snapshot
Progress of SGLT2 inhibitors in the treatment of common immune-related nephropathies
inferred← citeshttps://doi.org/10.1007/s12035-025-05457-5openalex-snapshot
Targeting Neurodegeneration with SGLT2is: From Molecular Mechanisms to Clinical Implications
inferred← citeshttps://doi.org/10.1016/j.biopha.2023.115025openalex-snapshot
Renal intrinsic cells remodeling in diabetic kidney disease and the regulatory effects of SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.1016/j.ejphar.2025.178237openalex-snapshot
Translational study of targeting Dynamin-1 and podocyte actin cytoskeleton to reduce proteinuria in chronic kidney disease
inferred← citeshttps://doi.org/10.1016/j.mehy.2024.111417openalex-snapshot
Could the administration of SGLT2i agents serve as a viable prophylactic approach against CNI-induced toxicities?
inferred← citeshttps://doi.org/10.1053/j.ajkd.2021.09.013openalex-snapshot
KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD
inferred← citeshttps://doi.org/10.1093/eurheartj/ehad389openalex-snapshot
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
inferred← citeshttps://doi.org/10.1093/ndt/gfab316openalex-snapshot
The management of membranous nephropathy—an update
inferred← citeshttps://doi.org/10.1093/ndt/gfad175openalex-snapshot
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis
inferred← citeshttps://doi.org/10.1111/dom.16007openalex-snapshot
Slowing the progression of diabetic and non‐diabetic kidney disease: A summary of the current evidence base for sodium‐glucose co‐transporter‐2 inhibitors
inferred← citeshttps://doi.org/10.1111/dom.16385openalex-snapshot
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors
inferred← citeshttps://doi.org/10.1111/dom.70003openalex-snapshot
Association between sodium‐glucose cotransporter 2 inhibitor use and clinical outcomes in patients with type 2 diabetes after urinary tract infection
inferred← citeshttps://doi.org/10.1152/ajprenal.00130.2025openalex-snapshot
Dapagliflozin, in addition to ramipril, ameliorates kidney disease progression in mice with Alport syndrome
inferred← citeshttps://doi.org/10.1177/23971983241301231openalex-snapshot
Decreased prevalence and altered clinical phenotype of systemic sclerosis and other autoimmune connective tissue diseases in type 1 and type 2 diabetes: A cross-sectional observational study
inferred← citeshttps://doi.org/10.1530/ec-23-0005openalex-snapshot
SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
inferred← citeshttps://doi.org/10.2174/0127724328313815240723044625openalex-snapshot
The Effect of Dapagliflozin on Heart Function in Animal Models of Cardiac Ischemia, A Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.32932/pjnh.2023.03.234openalex-snapshot
SGLT-2 Inhibitors and Renal Outcomes in Non-Diabetic Patients: A Systematic Review
inferred← citeshttps://doi.org/10.33393/gcnd.2022.2423openalex-snapshot
SGLT2 inhibitors: suggestions from the amphibian world
inferred← citeshttps://doi.org/10.33590/emjnephrol/22-00083openalex-snapshot
SGLT2 Inhibitors for Nephrologists
inferred← citeshttps://doi.org/10.3390/antiox13121540openalex-snapshot
From Adipose to Ailing Kidneys: The Role of Lipid Metabolism in Obesity-Related Chronic Kidney Disease
inferred← citeshttps://doi.org/10.3390/jcm13040956openalex-snapshot
Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side
inferred← citeshttps://doi.org/10.3390/kidneydial2040049openalex-snapshot
Remission of Proteinuria in a Patient Affected by Crescentic IgA Nephropathy with Rapidly Progressive Glomerulonephritis Treated by Sodium-Glucose Cotransporter-2 Inhibitors: Casual or Causal Relationship?
inferred← citeshttps://doi.org/10.3390/ph18081130openalex-snapshot
Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs
inferred← citeshttps://doi.org/10.34172/npj.2023.10606openalex-snapshot
Promising role of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.